MedTrace Logo

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

NCT03097939 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2023-10-11

No results posted yet for this study

Summary

The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC). Hence, this is a combination study of nivolumab and ipilimumab in Epstein-Barr virus (EBV) driven nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Ipilimumab

1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks

DRUG

Nivolumab

3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Darren, Wan-Teck Lim, MD · National Cancer Centre, Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03097939 on ClinicalTrials.gov